The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Atezolizumab after CRT in limited stage small-cell lung cancer
Bjorn Henning Gronberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, discusses findings from a randomized Phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). Despite promising immunotherapy results in extensive-stage disease and locally advanced NSCLC, this trial found no survival benefit from adding durvalumab consolidation therapy after chemoradiation in limited-stage patients. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The treatment of limited-stage small cell lung cancer has been concurrent chemo and radiotherapy for 25 years and we also see that there hasn’t been much improvement in survival looking at the population-based studies. Approximately one third of patients are cured so there’s definitely a need for better treatment. We know that immunotherapy when added to chemotherapy prolonged survival in extensive stage small cell lung cancer...
The treatment of limited-stage small cell lung cancer has been concurrent chemo and radiotherapy for 25 years and we also see that there hasn’t been much improvement in survival looking at the population-based studies. Approximately one third of patients are cured so there’s definitely a need for better treatment. We know that immunotherapy when added to chemotherapy prolonged survival in extensive stage small cell lung cancer. And we also know from studies of locally advanced and non-small cell lung cancer that immunotherapy consolidation after chemotherapy improves survival. So that was the background and I think based on those data it was quite natural for us to move on with a study design like in this trial. Overall there was no difference in survival between the experimental group those patients who received atezolizumab and those who were randomized to observation. There was maybe a little indication of an effect looking at the PFS curves, but that difference was also not statistically significant. So overall, we didn’t find any benefit of the atezolizumab in this setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Employment – Lilly (I)
Stock and Other Ownership Interests – Lilly (I)
Honoraria – AstraZeneca; BMS Norway; Gilead Sciences; Janssen; Lilly; MSD; Pfizer
Consulting or Advisory Role – Accord Healthcare; AstraZeneca; Janssen; MSD
Research Funding – AstraZeneca (Inst); Roche (Inst)
